☆ 4.7 Review

A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies

INTERNATIONAL IMMUNOPHARMACOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Hematology

SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group

Jose Luis Pinana et al.

Summary: This multicenter study observed SARS-CoV-2 antibody detection in allogeneic and autologous hematopoietic stem cell transplant recipients post-vaccination, with most recipients showing detectable antibodies. Factors associated with lower antibody detection included lymphopenia, active GvHD, and timing of vaccination in allo-HSCT; and non-Hodgkin's lymphoma and corticosteroid therapy in ASCT recipients. These findings suggest considerations for monitoring SARS-CoV-2 antibodies in immunocompromised patients following stem cell transplants.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

添加到收藏夹

Article Hematology

Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting

Moshe Mittelman et al.

Summary: Limited evidence suggests that COVID-19 vaccines may be less effective in patients with impaired immunity. A study on patients with hematological neoplasms showed that vaccinated patients had a higher risk of COVID-19 infection, hospitalization, and death compared to vaccinated controls. Patients receiving treatment had an even higher risk. Ways to enhance COVID-19 immunity in this patient population should be explored.

BLOOD (2022)

添加到收藏夹

Letter Biophysics

Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation

Marco Salvini et al.

BONE MARROW TRANSPLANTATION (2022)

添加到收藏夹

Letter Hematology

Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors

Wei Yee Chan et al.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Letter Hematology

Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant

Amandine Le Bourgeois et al.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Article Hematology

T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies

Vincenzo Marasco et al.

Summary: The study evaluated the serological and T-cell responses of lymphoid malignancy patients after mRNA vaccination, finding that some patients, especially those receiving anti-CD20 antibody treatment, may not effectively develop protective antibodies. T-cell responses were detected in most patients, even in seronegative individuals, but a small percentage of cases had no cellular or humoral responses. This raises concerns about the vaccine efficacy for LM patients, highlighting the need for continued protective measures.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Article Hematology

Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres

Ondrej Susol et al.

Summary: The mRNA COMIRNATY vaccine has been administered to 392 patients with a two-dose regimen, resulting in an overall antibody response of 70%. The initial results of administering a third dose to 80 patients who did not achieve seroconversion or had a weak response show promise, especially for patients on anti-CD38 therapy.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Article Oncology

Original Research Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events - a retrospective cohort study

Maximilian J. Mair et al.

Summary: This study demonstrates improved antibody levels in patients with cancer after the third vaccination dose with an acceptable side-effect profile. However, lower antibody levels compared to controls highlight the need for further follow-up studies and dedicated trials.

EUROPEAN JOURNAL OF CANCER (2022)

添加到收藏夹

Review Hematology

Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia

Marta Morawska

Summary: Patients with chronic lymphocytic leukemia have limited response to COVID-19 vaccination, with less than half developing antibody response, leaving them at risk of infection. Factors contributing to inadequate response include disease-related immune dysregulation, patient-related factors, and therapy-related factors.

EUROPEAN JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Letter Hematology

mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis

Stefano Molica et al.

EUROPEAN JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Article Oncology

Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study

Vivek Naranbhai et al.

Summary: The study investigated the immune responses to SARS-CoV-2 vaccines in cancer patients, showing that the vaccine-induced immune responses were quantitatively lower in cancer patients compared to healthy controls, recommending antibody testing to identify those who may benefit from additional vaccine doses.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Letter Oncology

Cellular response to COVID-19 vaccines in hematologic malignancies patients: a new hope for non-responders?

Imane Saad Albichr et al.

LEUKEMIA & LYMPHOMA (2022)

添加到收藏夹

Article Oncology

Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations

Maximilian J. Mair et al.

Summary: This study found that cancer patients can develop anti-SARS-CoV-2 antibodies after vaccination, but at lower levels compared to healthcare workers. Further research on vaccination effects in cancer patients is needed.

JAMA ONCOLOGY (2022)

添加到收藏夹

Letter Hematology

Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis

Giovanni Caocci et al.

ANNALS OF HEMATOLOGY (2022)

添加到收藏夹

Letter Hematology

The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2

Francesco Marchesi et al.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine

Maria Gavriatopoulou et al.

Summary: Vaccination against SARS-CoV-2 in patients with hematological malignancies, such as Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia, and Non-Hodgkin Lymphoma, results in lower production of neutralizing antibodies compared to controls, highlighting the importance of continued vaccination and potential need for booster doses in these patients with suboptimal responses.

CLINICAL AND EXPERIMENTAL MEDICINE (2022)

添加到收藏夹

Article Hematology

Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD20 antibodies

Ronit Gurion et al.

Summary: This study aimed to assess the humoral response of lymphoma patients after receiving two doses of BNT162b2 Pfizer vaccine and identify factors affecting the response. The results showed that lymphoma patients, especially those recently treated with anti-CD20 monoclonal antibodies, failed to develop sufficient humoral response to the vaccine. This low level of response could make them more vulnerable to COVID-19, highlighting the need for a different vaccination schedule for this population.

HAEMATOLOGICA (2022)

添加到收藏夹

Article Hematology

Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Ohad Benjamini et al.

Summary: Patients with chronic lymphocytic leukemia (CLL) have a suboptimal humoral response to vaccination. In this study, the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in CLL patients were investigated. The vaccine was found to be safe, but its efficacy was limited, especially in treated patients.

HAEMATOLOGICA (2022)

添加到收藏夹

Letter Oncology

Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas

Francesco Marchesi et al.

LEUKEMIA (2022)

添加到收藏夹

Editorial Material Oncology

Impaired immune responses in blood cancers improved by third COVID-19 vaccine dose

Sean Hua Lim et al.

Summary: People with lymphoma have compromised immune response to vaccination, except for those who received anti-CD20 antibody therapy within a year prior to vaccination. A study of 457 lymphoma patients showed improvement in antibody and T cell responses after the third vaccine dose.

NATURE CANCER (2022)

添加到收藏夹

Article Oncology

COVID-19 vaccination immune response in patients with solid organ and haematologic malignancies: call for active monitoring

Laudy Chehade et al.

Summary: While COVID-19 vaccines have shown high efficacy in the general population, patients on active anti-cancer therapy may have reduced immune response to the vaccine, highlighting the importance of maintaining precautionary measures and actively monitoring immune response post-vaccination.

ECANCERMEDICALSCIENCE (2021)

添加到收藏夹

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Shengli Xia et al.

Summary: The inactivated SARS-CoV-2 vaccine, BBIBP-CorV, demonstrated safety and immunogenicity in two age groups. Humoral responses against SARS-CoV-2 were induced in all vaccine recipients by day 42. A two-dose immunisation with 4 mu g vaccine on days 0 and 21 or days 0 and 28 achieved higher neutralising antibody titres compared to other dosing schedules.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Letter Hematology

Attenuated humoral immune response following anti-SARSCoV-2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis

Neta Schiller Salton et al.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Meeting Abstract Hematology

Production of Anti-Spike Antibodies in Response to COVID Vaccine in Lymphoma Patients

Alexandra Della Pia et al.

BLOOD (2021)

添加到收藏夹

Meeting Abstract Hematology

Neutralizing Antibody Responses Against Sars-Cov-2 in Patients with Plasma Cell Disorders Who Are on Active Treatment after Two Doses of mRNA Vaccination

Al-Ola Abdallah et al.

BLOOD (2021)

添加到收藏夹

Letter Oncology

Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma

Adolfo Aleman et al.

CANCER CELL (2021)

添加到收藏夹

Letter Oncology

Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer

Duncan R. McKenzie et al.

CANCER CELL (2021)

添加到收藏夹

Article Oncology

Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer

Jane C. Figueiredo et al.

Summary: The study showed that patients with solid tumors had higher and sustained antibody levels after receiving the mRNA-1273 vaccine compared to those with hematologic malignancies. Furthermore, patients receiving B-cell targeted treatment had lower antibody responses. Additionally, solid tumor patients who received immune checkpoint inhibitors before vaccination had lower sustained antibody levels than those who received treatment after vaccination.

CANCER RESEARCH (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

添加到收藏夹

Review Oncology

Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis

Son Tran et al.

Summary: COVID-19 vaccines elicit weaker and heterogeneous serological responses in cancer patients after a single dose, but significantly increase seropositivity rates after the second dose; however, antibody titres remain lower compared to healthy controls. Patients with haematological malignancies exhibit significantly lower seroconversion rates than those with solid tumours.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Immunology

Administration of COVID-19 vaccines in immunocompromised patients

Manica Negahdaripour et al.

Summary: This review focuses on the challenges and considerations of COVID-19 vaccination in specific populations, such as patients with autoimmune diseases and those receiving immunosuppressive treatments. While confirmed data is lacking, reaching a consensus on vaccination for these populations is crucial, along with the need for further research and clinical trials to address these issues.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

添加到收藏夹

Article Oncology

Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients

Lorenzo Canti et al.

Summary: Response to SARS-CoV-2 mRNA vaccination in allogeneic hematopoietic stem cell transplantation recipients is influenced by chronic GVHD and rituximab therapy. Immunological markers could assist in identifying allo-HCT patients at risk of poor antibody response to mRNA vaccination.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Article Oncology

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Livio Pagano et al.

Summary: This study analyzed baseline characteristics and predictors of mortality in hematological malignancy patients with COVID-19. Results showed that a high percentage of patients developed severe/critical symptoms, with a mortality rate of 31.2%, although improved prevention measures have decreased mortality rates despite an increase in reported cases.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Letter Oncology

Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls

Samuel Bitoun et al.

Summary: Patients with multiple myeloma have a higher risk of severe forms of COVID-19. Despite showing diminished response to vaccines, mRNA vaccines could still be a gamechanger. The study found that multiple myeloma patients had lower levels of Anti-Spike IgG compared to healthy controls, but a high percentage still achieved a humoral response. Uncontrolled disease under treatment was identified as a potential risk factor for non-response to the COVID-19 vaccine.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Letter Oncology

Serum antibody response in patients with philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines

Kathryn E. Kozak et al.

LEUKEMIA (2021)

添加到收藏夹

Letter Biochemistry & Molecular Biology

Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients

Cong Zeng et al.

Summary: Cancer patients, especially those with CLL and NHL, exhibit lower neutralizing antibody responses after receiving two doses of mRNA vaccines, indicating an urgent need for novel immunization strategies against SARS-CoV-2.

CELL AND BIOSCIENCE (2021)

添加到收藏夹

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia have a significantly impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine, which is influenced by disease activity and treatment.

BLOOD (2021)

添加到收藏夹

Letter Hematology

Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose

Evangelos Terpos et al.

BLOOD (2021)

添加到收藏夹

Article Oncology

Cocooning Against COVID-19: The Argument for Vaccinating Caregivers of Patients With Cancer

Maresa C. Woodfield et al.

Summary: It is suggested that cocoon vaccination strategies should be used to protect cancer patients in the COVID-19 vaccination race. Medical systems specializing in cancer care should support education and vaccination campaigns targeting informal caregivers and household contacts, in addition to cancer patients.

CANCER (2021)

添加到收藏夹

Review Immunology

Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia

Alessandro Allegra et al.

Summary: Secondary immunodeficiency is common in patients with hematological malignancies, affecting their risk of infection and overall prognosis. Treatment strategies need to be personalized based on individual clinical and immunological conditions, with potential risks associated with vaccination such as decreased immune response and adverse reactions.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

Peter Bergman et al.

Summary: This prospective clinical trial investigated the safety and efficacy of the BNT162b2 mRNA vaccine in immunocompromised patients and healthy controls. The vaccine was found to be safe in immunocompromised patients, but with a lower seroconversion rate compared to healthy controls. Additional vaccine doses may be needed to improve immunity in certain immunocompromised patient groups.

EBIOMEDICINE (2021)

添加到收藏夹

Review Oncology

Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review

Deniz C. Guven et al.

Summary: In summary, cancer patients, especially those with hematologic malignancies and undergoing active treatment, had significantly lower seroconversion rates after COVID-19 vaccination. Further research is urgently needed to explore approaches to improve vaccine efficacy and identify novel treatment options for these patients.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

Fulvia Pimpinelli et al.

Summary: The study assessed the safety and immunogenicity of the BNT162b2 mRNA vaccine in hematological patients, finding lower response rates in multiple myeloma patients. It suggests that these patients should continue to maintain protective measures and monitor vaccine effectiveness post-vaccination.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Article Immunology

Humoral and Cellular Vaccination Responses against SARS-CoV-2 in Hematopoietic Stem Cell Transplant Recipients

Monika Lindemann et al.

Summary: The cellular response to SARS-CoV-2 vaccination and infection in HSCT recipients remains unclear. The study found that HSCT patients vaccinated twice had significantly higher SARS-CoV-2 IgG antibodies compared to pre-vaccination. However, their ELISpot responses were reduced to less than 33% of controls. Female patients and healthy controls showed higher antibody responses post-vaccination, while cellular immunity was diminished in patients regardless of sex.

VACCINES (2021)

添加到收藏夹

Article Immunology

The COVID-19 mRNA BNT163b2 Vaccine Was Well Tolerated and Highly Immunogenic in Young Adults in Long Follow-Up after Haematopoietic Stem Cell Transplantation

Agnieszka Matkowska-Kocjan et al.

Summary: The study finds that young adults who have undergone allogeneic haematopoietic stem cell transplantation tolerate the COVID-19 mRNA vaccine well and demonstrate an immune response. In addition, higher antibody titers were observed in COVID-19 convalescents, with an inverse correlation between the time from HSCT and titers after receiving the second vaccine dose.

VACCINES (2021)

添加到收藏夹

Article Immunology

Antibody Responses after a Third Dose of COVID-19 Vaccine in Kidney Transplant Recipients and Patients Treated for Chronic Lymphocytic Leukemia

Julien Marlet et al.

Summary: This retrospective study aimed to characterize antibody responses induced by a third dose of mRNA COVID-19 vaccine in kidney transplant recipients and CLL patients. Results showed a moderate increase in SARS-CoV-2 anti-spike IgG levels after the third dose, but the impact on prevalence of anti-spike IgG & GE; 30 BAU/mL was limited in these immunocompromised patients.

VACCINES (2021)

添加到收藏夹

Article Oncology

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Leticia Monin et al.

Summary: The study aimed to evaluate the safety and immunogenicity of the BNT162b2 vaccine in cancer patients. The results showed poor efficacy of a single vaccine dose in cancer patients, with significantly increased immunogenicity in solid cancer patients after a vaccine boost at day 21. Therefore, it is recommended to prioritize cancer patients for an early second dose on day 21.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia

Lindsey E. Roeker et al.

LEUKEMIA (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose

Fabio Fiorino et al.

Summary: Immunization with mRNA SARS-CoV-2 vaccines in patients with myelofibrosis (MF) leads to slower kinetics of antibody responses, especially in those treated with ruxolitinib. The study suggests the potential need for a third vaccine dose in these patients.

BIOMEDICINES (2021)

添加到收藏夹

Article Oncology

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Aakash Desai et al.

Summary: The rapid development of COVID-19 vaccines has provided new hope of mitigating the disease, and it is necessary to prioritize cancer patients, including those participating in oncology clinical trials, for vaccination. Data on the safety, tolerability and efficacy of the vaccines in patients with cancer are currently limited, but the benefits of vaccination are likely to far outweigh the risks of adverse events.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹

Editorial Material Hematology

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma

Sarah Bird et al.

LANCET HAEMATOLOGY (2021)

添加到收藏夹

Review Medicine, General & Internal

Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines

Bogdan Doroftei et al.

Summary: After analyzing 19 relevant articles, it was concluded that among the eleven vaccines, Pfizer-BioNTech (about 95%), Moderna (about 94%), and Sputnik V (about 92%) showed an efficacy greater than 90%, while Oxford-AstraZeneca was only about 81% effective. Additionally, Moderna, Sputnik V, and Oxford-AstraZeneca also reduced the occurrence of severe adverse reactions.

DIAGNOSTICS (2021)

添加到收藏夹

Letter Hematology

Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and/or immunotherapy

Sandra Lockmer et al.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Article Hematology

BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies

Katrin Herzog Tzarfati et al.

Summary: Patients with hematologic malignancies have a reduced immune response to the COVID-19 vaccine, with lower seropositivity rates and antibody titers, increasing their risk for severe infection.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Letter Hematology

Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib

Paola Guglielmelli et al.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Letter Hematology

Serologic response to mRNA COVID-19 vaccination in lymphoma patients

Eric Matthew Jurgens et al.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Article Hematology

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies

Paola Ghione et al.

BLOOD (2021)

添加到收藏夹

Article Hematology

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy

Binod Dhakal et al.

BLOOD (2021)

添加到收藏夹

Article Medicine, General & Internal

Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals

Elizabeth Fraley et al.

Summary: This study characterized humoral immune responses during vaccination with the BNT162b2 vaccine in individuals with or without prior history of natural SARS-CoV-2 infection, demonstrating differences in antibody levels and epitope specificity between the two groups. The findings support the consideration of prior infection history as a guide for future vaccination strategies and provide valuable insights for vaccine development.

BMC MEDICINE (2021)

添加到收藏夹

Article Hematology

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia

Patrick Harrington et al.

Summary: This study found that most patients with CML developed antibodies and polyfunctional T-cell responses after receiving a single dose of the SARS-CoV-2 BNT162b2 vaccine, demonstrating good immunogenicity in this patient population compared to those with solid tumors or lymphoid hematological malignancies.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Letter Hematology

Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies

Thomas A. Fox et al.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Article Hematology

Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients

Magdalena Benda et al.

Summary: The study evaluated the serological response, predictive markers, and safety of BNT162b2 in haemato-oncological patients. Results showed that over 70% of oncological patients and around 70% of haematological patients developed antibodies after vaccination, with some patients at risk of serological non-response. Vaccination was well tolerated with low risk of severe side effects.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Article Hematology

Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma

Irit Avivi et al.

Summary: This single-centre study found that multiple myeloma (MM) patients had a lower seropositive response rate to the BNT162b2 vaccine compared to healthy controls, with older age, hypogammaglobulinaemia, and exposure to multiple anti-myeloma drugs associated with lower response rates. The vaccine was found to be safe and provide high seropositivity in MM patients independent of treatment type.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Letter Hematology

Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms

Onima Chowdhury et al.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Letter Oncology

Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient

Joshua A. Hill et al.

CANCER CELL (2021)

添加到收藏夹

Article Oncology

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer

Alfredo Addeo et al.

Summary: Among cancer patients, most (94%) achieved seroconversion after receiving two vaccine doses. Seroconversion rates and antibody titers in patients with hematological malignancy were significantly lower than those with solid tumors. None of the patients with history of anti-CD-20 antibody in the 6 months before vaccination developed antibody response.

CANCER CELL (2021)

添加到收藏夹

Article Oncology

Seroconversion rates following COVID-19 vaccination among patients with cancer

Astha Thakkar et al.

Summary: Most cancer patients show high seroconversion rates after receiving COVID-19 vaccines, but those with hematologic malignancies, especially after highly immunosuppressive therapies, exhibit lower conversion rates. Patients on immune checkpoint inhibitor therapy or hormonal therapy display high conversion rates.

CANCER CELL (2021)

添加到收藏夹

Letter Oncology

Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies

Lee Greenberger et al.

CANCER CELL (2021)

添加到收藏夹

Letter Oncology

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies

Lee M. Greenberger et al.

CANCER CELL (2021)

添加到收藏夹

Letter Oncology

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

Oliver Van Oekelen et al.

CANCER CELL (2021)

添加到收藏夹

Letter Oncology

Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer

Sidse Ehmsen et al.

CANCER CELL (2021)

添加到收藏夹

Letter Oncology

Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer

Mario Mairhofer et al.

CANCER CELL (2021)

添加到收藏夹

Article Oncology

The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience

Gabriel Revon-Riviere et al.

Summary: The study evaluated the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with solid tumors, showing good tolerability and effectiveness in preventing COVID-19 infection in this population. Additional monitoring is needed to confirm these preliminary results and determine long-term vaccination effectiveness.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Letter Oncology

COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients

Giovanni Del Poeta et al.

HEMATOLOGICAL ONCOLOGY (2021)

添加到收藏夹

Letter Cell Biology

Immunogenicity and safety of BNT162b2 COVID-19 vaccine in a chronic lymphocytic leukaemia patient

Chiara Agrati et al.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2021)

添加到收藏夹

Letter Oncology

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia

Fulvia Pimpinelli et al.

Summary: Among 42 Philadelphia negative myeloproliferative neoplasm patients receiving systemic active treatment, those with myelofibrosis showed significantly lower response to the anti-SARS-CoV-2 BNT162b2 vaccine compared to patients with essential thrombocythemia and polycythemia vera in terms of IgG titers and seroprotection rates. The ongoing treatment with Ruxolitinib in some patients may be associated with reduced vaccine immunogenicity, but further large prospective studies are needed to confirm this finding.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Letter Medicine, General & Internal

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients

Rabah Redjoul et al.

LANCET (2021)

添加到收藏夹

Letter Oncology

Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia

Tamar Tadmor et al.

LEUKEMIA (2021)

添加到收藏夹

Letter Oncology

Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms

Patrick Harrington et al.

LEUKEMIA (2021)

添加到收藏夹

Article Oncology

Response to mRNA vaccination for COVID-19 among patients with multiple myeloma

Samuel D. Stampfer et al.

Summary: Patients with multiple myeloma have impaired responses to mRNA vaccination against COVID-19, with those with active disease showing poorer responses. Factors such as age, renal function, immunoglobulin levels, among others, can predict vaccine responsiveness in these patients. Additionally, patients vaccinated with mRNA-1273 had higher anti-spike antibody levels compared to those vaccinated with BNT162b2.

LEUKEMIA (2021)

添加到收藏夹

Letter Oncology

Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies

Daniel Re et al.

LEUKEMIA & LYMPHOMA (2021)

添加到收藏夹

News Item Biotechnology & Applied Microbiology

Pfizer's COVID-19 vaccine secures first full FDA approval

Asher Mullard

NATURE REVIEWS DRUG DISCOVERY (2021)

添加到收藏夹

Letter Oncology

Varicella-Zoster virus reactivation following SARS-CoV-2 immunization in two patients with leukemia

Catherine E. Foster et al.

PEDIATRIC BLOOD & CANCER (2021)

添加到收藏夹

Editorial Material Oncology

Serological response to COVID-19 vaccination in patients with cancer older than 80 years

Daniela Iacono et al.

JOURNAL OF GERIATRIC ONCOLOGY (2021)

添加到收藏夹

Article Cell Biology

Thromboembolism after COVID-19 vaccine in patients with preexisting thrombocytopenia

Alessandro Mauriello et al.

Summary: Vaccination is crucial in reducing severe disease and death caused by SARS-CoV-2 infection, but concerns have been raised regarding unusual adverse drug reactions, including vaccine-induced immune thrombotic thrombocytopenia (VITT). While the overall safety of the vaccines is highlighted by low frequency of adverse reactions in the UK, some cases of fatal thrombotic events have been reported, with abnormalities in platelet counts and PF4 antibodies observed.

CELL DEATH & DISEASE (2021)

添加到收藏夹

Article Oncology

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies

Florent Malard et al.

Summary: This study evaluated the safety and immunogenicity of the BNT162b2 vaccine in patients with hematological malignancies. It found that only around half of the patients may achieve effective immune protection against COVID-19 after receiving two doses of the vaccine. Factors such as being male, receiving B-cell targeting treatment, and having low CD19(+) B-cell levels were associated with a decreased probability of achieving a protective level of anti-S IgG after the second dose.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹

Article Oncology

Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia

H. Parry et al.

Summary: CLL patients have lower antibody responses after both first and second Covid-19 vaccine doses compared to healthy donors. Patients currently treated with BTK inhibitors or with IgA deficiency are more likely to fail to generate an antibody response after the second vaccine. This study supports the need for optimizing vaccination strategies in CLL patients, potentially including the use of booster vaccines.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹

Article Oncology

The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment

Evangelos Terpos et al.

Summary: Recent data shows suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Specifically, patients with multiple myeloma (MM) exhibit lower production of neutralizing antibodies (NAbs) after vaccination compared to healthy controls, especially when undergoing treatment with anti-CD38 or belamaf. Timely vaccination, possibly during treatment-free periods, is emphasized for this group of patients.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹

Article Immunology

COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial

Chiara Agrati et al.

Summary: This article reviews the immune responses to vaccination in patients with malignancy, neurological and immunological disorders, proposing the VAX4FRAIL study to evaluate immune responses in this population.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Hematology

Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study

Kazimieras Maneikis et al.

Summary: Patients with haematological malignancies exhibit blunted and heterogeneous antibody responses after receiving the full course of BNT162b2 mRNA vaccination. Those actively treated with BTKIs, ruxolitinib, venetoclax, or anti-CD20 antibody therapies show the poorest responses, while patients who received tyrosine kinase inhibitors or various types of stem-cell transplantation had higher antibody responses. Severe breakthrough SARS-CoV-2 infections and deaths in fully vaccinated patients with haematological malignancies highlight the importance of continued adherence to non-pharmacological interventions and household vaccination.

LANCET HAEMATOLOGY (2021)

添加到收藏夹

Editorial Material Hematology

Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma

Sean H. Lim et al.

LANCET HAEMATOLOGY (2021)

添加到收藏夹

Letter Oncology

Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease

Thomas A. Ollila et al.

JAMA ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study

Evangelos Terpos et al.

Summary: The urgency of the COVID-19 pandemic has accelerated vaccine development, but patients with hematological malignancies show suboptimal immune response to the SARS-CoV-2 vaccine, highlighting the need for timely vaccination during a treatment-free period and continuous vigilance on infection control measures.

CANCERS (2021)

添加到收藏夹

Article Oncology

Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+B-Lymphocyte Count and Anti-CD38 Treatment

Susanne Ghandili et al.

Summary: The global impact of the COVID-19 pandemic has prompted rapid development of multiple anti-SARS-CoV-2 vaccines. Data on the efficacy of these vaccines in patients with hematological malignancies, especially plasma cell neoplasia, are limited. An observational study of 82 patients with multiple myeloma and related plasma cell neoplasia found that 23% had positive SARS-CoV-2 spike protein antibody titers after the first vaccination. Higher CD19+ B lymphocyte counts and treatment with anti-CD38 antibodies were associated with significantly higher antibody titers, while older age and poorly controlled disease correlated negatively with antibody levels. Majorities of these patients may require booster vaccinations due to poor initial response.

CANCERS (2021)

添加到收藏夹

Article Oncology

COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience

Alfred Chung Pui So et al.

Summary: This study investigated the safety of COVID-19 vaccines in cancer patients at a center in London, finding that these patients generally tolerated the vaccines well with mild reactogenicity, experiencing common side effects such as sore arm, fatigue, and headaches. The results suggest that COVID-19 vaccines could be a feasible option for oncology patients, allowing for a return to pre-pandemic oncology care.

CANCERS (2021)

添加到收藏夹

Article Oncology

Immunological Response Against SARS-COV-2 After BNT162b2 Vaccine Administration Is Impaired in Allogeneic but Not in Autologous Stem Cell Transplant Recipients

Martina Chiarucci et al.

Summary: The efficacy of Covid-19 vaccine in HSCT recipients remains uncertain. This study showed that prior Rituximab in autologous HSCT and cyclosporine administration in allogeneic HSCT negatively impacted antibody response. Additionally, increased numbers of CD19+ B lymphocytes and CD56+ natural killer cells correlated significantly with antibody response.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Immunology

Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant

Djordje Atanackovic et al.

Summary: Research suggests that post-stem cell transplant patients may develop immunity against COVID-19, but a sufficient time interval is crucial. Patients with preexisting anti-SARS-CoV-2 immunity are at risk of losing protective immunity after transplantation. Some post-transplant patients may be incapable of mounting an immune response to a COVID-19 vaccine due to prophylactic suppression of T cell immunity.

VACCINES (2021)

添加到收藏夹

Article Oncology

Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment

M. Peeters et al.

Summary: The study found that cancer patients receiving COVID-19 vaccination experienced mostly mild to moderate local and systemic adverse events, with more frequent local adverse events following the booster dose. Additionally, immunized cancer patients had delayed and diminished antibody responses, particularly in those receiving chemotherapy or rituximab treatments.

ESMO OPEN (2021)

添加到收藏夹

Letter Medicine, General & Internal

Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant

Amandine Le Bourgeois et al.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Article Hematology

Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study

Maria Gavriatopoulou et al.

Summary: Immunocompromised patients with hematologic malignancies, particularly those with Waldenstroeurom macroglobulinemia (WM), have lower production of neutralizing antibodies (NAbs) against SARS-CoV-2 after COVID-19 vaccination compared with healthy controls on days 22 and 50 post-vaccination. Disease-related immune dysregulation and therapy-related immunosuppression are likely contributors to this suboptimal humoral response. Active treatment with specific medications is also associated with a diminished antibody response following vaccination.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma

C. Perry et al.

Summary: Patients with B-cell non-Hodgkin lymphoma (B-NHL) undergoing R/Obi treatment have impaired humoral response to the BNT162b2 mRNA COVID-19 vaccine. Longer time since exposure to R/Obi is associated with improved response rates to the COVID-19 vaccine. Multi-variable analysis reveals predictors for a positive serological response.

BLOOD ADVANCES (2021)

添加到收藏夹

Letter Hematology

Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies COMMENT

Jennifer L. Crombie et al.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Medicine, General & Internal

BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study

Galia Rahav et al.

Summary: The antibody response to the Pfizer-BioNTech vaccine varied significantly among different immunocompromised patients, suggesting the need for individual recommendations based on specific immunosuppression states.

ECLINICALMEDICINE (2021)

添加到收藏夹

Article Hematology

Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients

Haris Ali et al.

Summary: This study retrospectively reviewed 113 allogeneic hematopoietic stem cell transplant (HCT) patients who received SARS-CoV2 vaccines, and found that the vaccines were well tolerated in this group. Common side effects included myalgias/arthralgias, fatigue, injection site pain, and liver function abnormalities, as well as neutropenia and other hematologic issues.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

添加到收藏夹

Article Oncology

Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies

David J. Chung et al.

Summary: Patients with hematologic malignancy have compromised COVID-19 vaccine responses at baseline, which are further suppressed by certain therapies, leading to insufficient neutralizing capacity despite positive antibody titers. Refining vaccine response parameters is critical for guiding clinical care, including the consideration for booster vaccines in this vulnerable population.

BLOOD CANCER DISCOVERY (2021)

添加到收藏夹

Article Oncology

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study

Annika Fendler et al.

Summary: A cohort study evaluated 585 cancer patients following vaccination with BNT162b2 or AZD1222 vaccines, finding lower antibody responses in patients with hematological malignancies compared to those with solid tumors. Patients with hematological malignancies also had reduced neutralizing antibody responses compared to individuals without cancer. The study highlights the importance of managing cancer patients during the ongoing COVID-19 pandemic.

NATURE CANCER (2021)

添加到收藏夹

Article Oncology

Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy

Roni Tamari et al.

Summary: Cellular therapies render patients severely immunocompromised, and this study highlights the importance of vaccination against COVID-19 in this vulnerable population. Predictors of response to vaccination, such as time from therapy to vaccination and immune recovery post-therapy, are crucial in informing clinical decisions about optimal timing of vaccines and the need for booster doses.

BLOOD CANCER DISCOVERY (2021)

添加到收藏夹

Article Hematology

Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study

Ron Ram et al.

Summary: In this prospective evaluation, the BNT162b2 mRNA COVID-19 vaccine showed good tolerability and impressive immunogenicity in patients after allogeneic HCT or CART. While most adverse events were mild and transient, some significant hematologic events were observed, indicating the need for close monitoring of patients.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

添加到收藏夹

Article Oncology

Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients

Josef Singer et al.

Summary: Vaccination is the primary public health strategy to combat the COVID-19 pandemic, with solid tumor and hematologic patients being at higher risk of severe complications. Data on immune responses to COVID-19 vaccines in these patients are scarce. Complete vaccination is a valuable predictor for high anti-SARS-CoV-2 antibody responses in these vulnerable patient groups.

CANCERS (2021)

添加到收藏夹

Article Medicine, General & Internal

COVID-19 vaccination in patients with cancer: Position paper from the Indonesian Society of Hematology and Medical Oncology (ISHMO) of Semarang

Eko Adhi Pangarsa et al.

Summary: Cancer patients, especially those undergoing treatment, should consider receiving the COVID-19 vaccine to reduce the risk of severe infection. It is important to consult with a hematologist-medical oncologist to determine the most appropriate vaccine and timing, avoiding live-attenuated vaccines for those receiving chemotherapy. Additional risk factors for complications should also be taken into consideration for a comprehensive evaluation before vaccination.

BALI MEDICAL JOURNAL (2021)

添加到收藏夹

Letter Biophysics

COVID-19 outcomes in patients with hematologic disease

Florent Malard et al.

BONE MARROW TRANSPLANTATION (2020)

添加到收藏夹

Article Allergy

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Xiaochen Li et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

添加到收藏夹

Article Hematology

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Francesco Passamonti et al.

LANCET HAEMATOLOGY (2020)

添加到收藏夹

Letter Medicine, General & Internal

Case Fatality Rate of COVID-19: Meta-Analysis Approach

Amir Almasi-Hashiani et al.

ARCHIVES OF IRANIAN MEDICINE (2020)

添加到收藏夹

Article Public, Environmental & Occupational Health

Metaprop: a Stata command to perform meta-analysis of binomial data

Victoria N. Nyaga et al.

ARCHIVES OF PUBLIC HEALTH (2014)

添加到收藏夹

Article Oncology

Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network

A. Smith et al.

BRITISH JOURNAL OF CANCER (2011)

添加到收藏夹

Editorial Material Rheumatology

Good and Bad Memories Following Rituximab Therapy

E. William St Clair

ARTHRITIS AND RHEUMATISM (2010)

添加到收藏夹

Article Medicine, General & Internal

Measuring inconsistency in meta-analyses

JPT Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2003)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.